当前位置:
X-MOL 学术
›
Antimicrob. Agents Chemother.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Linezolid population pharmacokinetics in South African adults with drug-resistant tuberculosis.
Antimicrobial Agents and Chemotherapy ( IF 4.1 ) Pub Date : 2021-09-20 , DOI: 10.1128/aac.01381-21 Mahmoud Tareq Abdelwahab 1 , Sean Wasserman 1, 2, 3 , James C M Brust 4 , Keertan Dheda 5, 6, 7 , Lubbe Wiesner 1 , Neel R Gandhi 8, 9 , Robin M Warren 10 , Frederick A Sirgel 10 , Graeme Meintjes 2 , Gary Maartens 1, 2 , Paolo Denti 1
Antimicrobial Agents and Chemotherapy ( IF 4.1 ) Pub Date : 2021-09-20 , DOI: 10.1128/aac.01381-21 Mahmoud Tareq Abdelwahab 1 , Sean Wasserman 1, 2, 3 , James C M Brust 4 , Keertan Dheda 5, 6, 7 , Lubbe Wiesner 1 , Neel R Gandhi 8, 9 , Robin M Warren 10 , Frederick A Sirgel 10 , Graeme Meintjes 2 , Gary Maartens 1, 2 , Paolo Denti 1
Affiliation
BACKGROUNDLinezolid is widely used for drug-resistant tuberculosis (DR-TB) but has a narrow
therapeutic index. To inform dose optimisation, we aimed to characterise the population
pharmacokinetics of linezolid in South African participants with DR-TB and ...
中文翻译:
南非耐药结核病成人中利奈唑胺的群体药代动力学。
背景利奈唑胺广泛用于治疗耐药结核病(DR-TB),但治疗指数较窄。为了为剂量优化提供信息,我们旨在描述南非耐药结核病参与者中利奈唑胺的群体药代动力学特征......
更新日期:2021-09-21
中文翻译:
南非耐药结核病成人中利奈唑胺的群体药代动力学。
背景利奈唑胺广泛用于治疗耐药结核病(DR-TB),但治疗指数较窄。为了为剂量优化提供信息,我们旨在描述南非耐药结核病参与者中利奈唑胺的群体药代动力学特征......